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PAtherosclerosis
Associations of Long-Term and Early
Adult Atherosclerosis Risk Factors
With Aortic and Mitral Valve Calcium
George Thanassoulis, MD,*†# Joseph M. Massaro, PHD,**‡‡ Ricardo Cury, MD, Emily Manders, BS,*
Emelia J. Benjamin, MD, SCM,*††§§ Ramachandran S. Vasan, MD,* L. Adrienne Cupple, PHD,* **††
Udo Hoffmann, MD, MPH, Christopher J. O’Donnell, MD, MPH,*†¶¶ Sekar Kathiresan, MD*†‡§¶
Framingham, Boston, and Cambridge, Massachusetts; and Bethesda, Maryland
Objectives To determine the association of long-term exposure to atherosclerosis risk factors with valvular calcification.
Background Traditional atherosclerosis risk factors have been associated with aortic and mitral valve calcium in cross-
sectional studies, but long-term prospective data are lacking.
Methods This was a prospective, community-based cohort study with 27-year follow-up (median follow-up 26.9 years;
range 23.1 to 29.6 years). Participants from the Framingham Offspring Study (n  1,323, enrolled between
1971 and 1975, mean age at enrollment 34  9 years; 52% women) underwent cardiac multidetector com-
puted tomography assessment between 2002 and 2005. Associations between the long-term average of each
cardiovascular risk factor and valve calcium were estimated using logistic regression.
Results Aortic valve calcium was present in 39% of participants and mitral valve calcium in 20%. In multivariable mod-
els, the odds ratio for aortic valve calcium associated with every SD increment in long-term mean total choles-
terol was 1.74 (p  0.0001); with every SD increment in high-density lipoprotein cholesterol, it was 0.77 (p 
0.002); and with every 9 cigarettes smoked per day, it was 1.23 (p  0.002). Associations of similar magnitude
were seen for mitral valve calcium. The mean of 3 serum C-reactive protein measurements was associated with
mitral valve calcium (odds ratio: 1.29 per SD increment in C-reactive protein levels; p  0.002). A higher Fra-
mingham risk score in early adulthood (40 years age or younger) was associated with increased prevalence and
severity of aortic valve calcium measured 3 decades later.
Conclusions Exposure to multiple atherosclerotic risk factors starting in early to mid-adulthood is associated with aortic and
mitral valve calcium. Studies evaluating early risk factor modification to reduce the burden of valve disease are
warranted. (J Am Coll Cardiol 2010;55:2491–8) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.019“
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Kortic and mitral stenosis are among the most common forms
f valvular heart disease affecting the elderly. Valve calcification
recedes clinical stenosis and may represent an important
ntermediate phenotype for valve disease (1). Previously con-
idered a degenerative consequence of aging, valve calcification
nd the resulting valvular stenosis are now recognized as
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rosclerosis (2–7). However, the failure of lipid-lowering strat-
gies to prevent or slow the progression of valvular disease has
aised questions about the role of atherosclerosis risk factors in
alvular stenosis (8–11). Improved understanding of the role of
ardiovascular risk factors in valvular disease and the appropri-
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Risk Factors for Valve Calcium June 1, 2010:2491–8ate timing for their control could
provide insights into the preven-
tion of valvular disease. Athero-
sclerosis risk factors such as li-
poproteins, cigarette smoking, and
metabolic syndrome have been as-
sociated with valvular calcium in
several cross-sectional studies but
in only few prospective studies.
Prospective studies to date have
been limited by short-term
follow-up (2,12,13) and single as-
essments of risk factors (14), which may underestimate the
ong-term cumulative effects of cardiovascular risk factors
n valve calcium. In addition, contemporary rates of treat-
ent for cholesterol and other risk factors may attenuate the
ssociations of valvular disease with risk factors.
Prospective, longitudinal studies with repeated measure-
ents of risk factors could overcome these limitations.
ccordingly, using 25 years of longitudinal data from the
ramingham Offspring Study, we sought to evaluate the
ssociation of long-term exposure to atherosclerosis risk
actors with the prevalence of aortic valve and mitral valve
alcium in a community-based sample. We also sought to
stablish the association between an adverse risk factor
rofile in early to mid-adulthood and valvular calcification
easured nearly 3 decades later.
ethods
tudy sample. The Framingham Offspring Study was ini-
iated in 1971 as described previously (15,16). As part of a
ubstudy to measure subclinical cardiovascular disease,
,422 Offspring Study participants underwent cardiac mul-
idetector computed tomography (MDCT) between 2002
nd 2005 (Fig. 1). The MDCT study was described
reviously (17). Of the 1,422 participants who underwent
ardiac MDCT, we excluded 28 participants due to unin-
Abbreviations
and Acronyms
BMI  body mass index
CRP  C-reactive protein
CT  computed
tomography
HDL-C  high-density
lipoprotein cholesterol
MDCT  multidetector
computed tomography
Figure 1 Description of the Framingham Offspring Study and
Cardiac Multidetector Computed Tomography Substudy
hsCRP  high-sensitivity C-reactive protein.rerpretable computed tomography (CT) images and/or pre-
ious valve surgery. Of the 1,394 participants with inter-
retable images, 20 participants were excluded for not
ttending examination 7, 38 participants were excluded for
issing covariate data at examination 7, 9 participants who
ttended fewer than 4 of the 7 examinations were excluded,
nd 4 participants who attended at least 4 of the previous 7
xaminations but had all risk factors measured at only 3 or
ewer of the previous 7 examinations were excluded. After
ll exclusions, 1,323 participants remained eligible for the
resent investigation. Study protocols were approved by the
nstitutional Review Board of Boston University Medical
enter and Massachusetts General Hospital. Written in-
ormed consent was obtained from all participants.
therosclerosis risk factors. Risk factor information was
ollected from routine medical history, physical examina-
ion, and laboratory assessment. Total cholesterol and high-
ensity lipoprotein cholesterol (HDL-C) were determined
sing fasting blood samples and conventional biochemical
ethods. C-reactive protein (CRP) level was measured for
ach participant with a Dade Behring BN100 nephelometer
Dade Behring, Deerfield, Illinois) on fasting morning
erum samples. Body mass index (BMI) was calculated as
he weight in kilograms divided by the square of the height
n meters. A physician ascertained the number of cigarettes
moked daily and medication history during an interview.
lood pressure was determined in the left arm by a
phygmomanometer in subjects who had been seated for at
east 5 min. Hypertension was defined as a systolic blood
ressure 140 mm Hg, a diastolic blood pressure 90 mm
g, or antihypertensive treatment.
ardiac MDCT. Each participant underwent cardiac im-
ging using an 8-slice MDCT scanner (LightSpeed Ultra,
E Healthcare, Milwaukee, Wisconsin) as previously de-
cribed (18). Two scans were performed for each participant
sing a sequential scan protocol with prospective gating of
mage acquisition. Calcium measurements were performed
ffline on an Aquarius workstation (TeraRecon, San Mat-
eo, California).
alve calcium measurement. Calcium was defined as an
rea of 3 connected pixels with an attenuation of 130
ounsfield units. A modified Agatston scoring protocol was
sed to quantify the extent of calcium in the aortic and
itral valves. Aortic valve calcium was defined as calcium
eposits of the aortic cusps or nodular deposits at the
oaptation points of the aortic cusps. We excluded calcium
eposits restricted to the aortic wall. Mitral valve calcium
as defined as calcium deposits in the region of the annulus
nd/or the mitral valve leaflets.
Each set of 2 scans for each participant was initially read
or the presence or absence of valve calcium by either of 2
bservers (a cardiologist [S.K.] and a trained technician
E.M.]). If valve calcium was present on at least 1 of the 2
cans, the scan underwent an independent read, with the
esults of the first read blinded to a second observer (a
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June 1, 2010:2491–8 Risk Factors for Valve Calciumadiologist [R.C.]). Disagreement regarding the presence or
bsence of calcium was resolved by a consensus read
nvolving the cardiologist and the radiologist. To determine
participant’s valve calcium score, we first averaged the
esults from each of 2 scans read by the first observer and
hen averaged the results of the 2 observers. For scans
equiring a consensus read to adjudicate valve calcium, we
sed the calcium score determined by consensus between
he 2 observers. To determine interobserver variability, 2
bservers independently read a random sample of 112 scans.
nterobserver agreement for the presence or absence of
ortic valve calcium and mitral valve calcium was kappa 
.95 and kappa  1.00, respectively. Intraclass correlation
oefficients for aortic and mitral valve calcium scores were
.98 and 0.99, respectively.
tatistical analyses. Spearman correlation coefficients were
alculated for the relationship between aortic calcium and
itral valve calcium. We assessed agreement between aortic
nd mitral valve calcium scores by cross-classifying the
ortic and mitral calcium scores into a 5 5 matrix (the first
ategory consisted of scores of 0 and the other 4 categories
onsisted of scores within the first, second, third, and fourth
uartiles of valve calcium scores for those with detectable
alcium). A weighted kappa statistic was then calculated to
ummarize agreement between scores.
To examine the association of long-term average risk factors
ith valve calcium, we constructed multivariable logistic re-
ression models using p 0.10 as the significance criterion for
ovariates to be retained in the forward stepwise model
election process. The outcome variable was the presence or
bsence of valve calcium. Separate logistic regression models
ere fit with aortic valve calcium and mitral valve calcium as
he outcome measures. In addition, we separately modeled
lood pressure as a continuous variable (systolic and dia-
tolic blood pressures separately) and as a dichotomous
ariable based on our definition of hypertension (i.e., blood
ressure 140/90 mm Hg or antihypertensive treatment).
ge (at examination 7) and sex were forced in as covariates
n all models. The candidate predictor variables were total
holesterol, HDL-C, BMI, fasting glucose, CRP level,
igarettes smoked daily, lipid-lowering therapy, hyperten-
ion, and antihypertensive therapy. For continuous risk
actors, we modeled the exposure to be the average of
vailable values from the 7 examination cycle time points (3
xaminations were available for CRP). For categorical
ariables (lipid-lowering therapy, hypertension), we mod-
led the exposure as the proportion of examinations (out of
maximum of 7) where hypertension or lipid-lowering
herapy was present.
In a secondary analysis, to determine whether atheroscle-
osis risk factors present in early adulthood were related to
alve calcium, we restricted the risk factor determinations to
xamination cycles 1, 2, and 3 and studied the association of
isk factors measured at these early examinations with the 1resence of valve calcium. For these analyses, participants
ere required to have attended at least 2 of the 3 examina-
ions. For continuous risk factors, we considered the average
f available values, and for categorical risk factors, we
odeled the proportion of examinations (out of a maximum
f 3) where the risk factor was present.
Last, we evaluated the relationships between risk factors
easured at the baseline examination (1971 to 1975) and
alve calcium. Specifically, we estimated the prevalence and
everity of aortic and mitral valve calcium across categories
f Framingham coronary heart disease risk scores (19) based
n baseline risk factors (i.e., examination cycle 1). Trend
ests across cardiovascular risk categories were adjusted for
ge and sex. In a sensitivity analysis, we repeated this
nalysis in a sample restricted to participants 40 years of age
r younger (871 participants). All analyses were conducted
n SAS version 9.0 (SAS Institute, Cary, North Carolina).
dds ratios and 95% confidence intervals (CIs) are reported
or a 1-SD change in the predictor variable. A 2-sided
value 0.05 was considered significant.
esults
articipant characteristics. Participant characteristics for
he baseline examination (1971 to 1975) and for all 7
xaminations (1971 to 2001) are shown in Table 1. The
ean age of the participants at the baseline examination was
4  9 years and 64  9 years at the time of the CT scan.
edian follow-up time from baseline examination was 26.8
ears (range 23.1 to 29.6 years). On MDCT scans per-
ormed from 2002 to 2005, aortic valve calcium was detect-
ble in 39% (95% CI: 37% to 42%) of participants and
itral valve calcium was detectable in 20% (95% CI: 18% to
3%) of participants. The correlation between aortic and
itral valve calcium was 0.45 (p  0.0001). The agreement
etween aortic and mitral valve calcium scores was low
weighted kappa  0.34).
ultivariable associations of long-term risk factors and
ortic valve calcium. In multivariable models, older age at
aseline and higher values of the long-term average of several
isk factors (mean total cholesterol, BMI, and number of
igarettes smoked daily) were significantly associated with
ncreased odds of aortic valve calcium, whereas female sex and
igher values of the long-term average of HDL-C were
ssociated with reduced odds of aortic valve calcium (Table 2).
he average of CRP from 3 examinations (spanning 22
ears) was not associated with aortic valve calcium.
ultivariable associations of long-term risk factors and
itral valve calcium. Similar risk factors were associated
ith mitral valve calcium including age and the long-term
verages of total cholesterol, HDL-C, and number of
igarettes smoked daily (Table 2). In contrast to our findings
ith aortic valve calcium, long-term average CRP level was
ssociated with increased odds of mitral valve calcium (odds
atio: 1.29 per SD increment of CRP level; 95% CI: 1.10 to
.52; p  0.002).
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Risk Factors for Valve Calcium June 1, 2010:2491–8isk factors in early adulthood and valve calcium. As
hown in Table 3, early risk factors obtained in the first 3
xaminations (1971 to 1982) predicted the future presence
f valve calcium in a manner largely similar to the long-term
articipant Characteristics at Baseline Examination and Longitudinccording to the Pr sen e or Ab nc of Aortic and Mitral Valve CTable 1 Parti ipant Characteristics at Baseline Examination aAccording to the Presence or Absence of Aortic and M
Characteristic
Entire Sample
(N  1,323)
Baseline data (1971–1975)
Age, yrs 34 9
Female sex, % 52
Body mass index, kg/m2 24.7 4.1
Hypertension, % 14
Systolic blood pressure, mm Hg 119 14
Diastolic blood pressure, mm Hg 78 10
Total cholesterol, mg/dl 191 35
High-density lipoprotein cholesterol, mg/dl 52 16
Lipid-lowering therapy, % 0.3
Cigarette smoking, % 35
Cigarettes smoked daily 19 12
Diabetes, % 0.3
Fasting glucose, mg/dl 100 9
C-reactive protein, mg/dl 2.0 4.2
Longitudinal data* (examinations 1 to 7)
Body mass index, kg/m2 26.6 4.3
Hypertension, % 49
Systolic blood pressure, mm Hg 122 12
Diastolic blood pressure, mm Hg 77 7
Total cholesterol, mg/dl 200 29
High-density lipoprotein cholesterol, mg/dl 51 13
Lipid-lowering therapy, % 28
Cigarette smoking, % 50
Cigarettes smoked daily 10 9
Diabetes, % 37
Fasting glucose, mg/dl 97 14
C-reactive protein,† mg/dl 2.6 2.9
Valve calcium score median (1st and 3rd quartiles) —
ontinuous variables presented as mean  SD. To convert values for cholesterol to millimoles pe
vailable values during follow-up (examinations 1 through 7), whereas categorical variables are re
hrough 7). †C-reactive protein values are the mean of measurement at a maximum of 3 time poi
f 3 time points (examinations 2, 6, and 7).
ssociation of Long-Term Average of Individual Atherosclerosis RisExaminations 1 Through 7) With the Presence of Aorti and MitraTable 2 Ass ciation of Long-Term Average of Individu l Atheros(Examinations 1 Through 7) With the Presence of Aort
Aortic Va
Adjusted OR 9
Age, per SD 3.25 2.
Female (vs. male) sex 0.56 0.
Mean total cholesterol, per SD 1.74 1.
Mean high-density lipoprotein cholesterol, per SD 0.77 0.
Body mass index, per SD 1.21 1.
Cigarettes smoked daily, per SD 1.23 1.
Mean C-reactive protein, per SD —
tepwise logistic regression models were constructed with outcome variable of the presence of aor
through 7): age, sex, total cholesterol, high-density lipoprotein cholesterol, hypertension, body mherapy. Predictor variables with p  0.10 are presented.
CI  confidence interval; OR  odds ratio.verage across all 7 examinations. Exceptions included the
resence of a relationship between early BMI and mitral
alve calcium and the absence of a relationship between
itral valve calcium and either sex or HDL-C.
sk Factorsmngitudinal Risk Factors
Valve Calcium
Aortic Valve Calcium Mitral Valve Calcium
nt
04)
Present (Score >0)
(n  519)
Absent
(n  1,053)
Present (Score >0)
(n  270)
8 39 8 32 9 41 8
42 52 52
4.1 25.8 3.9 24.4 4.1 25.8 3.7
20 12 21
14 122 14 119 14 122 14
10 80 9 77 10 80 9
32 207 34 187 34 207 35
15 51 16 52 16 52 16
.3 0.4 0.1 1.1
39 35 36
11 21 12 19 11 22 13
.1 0.6 0.0 1.5
8 101 9 99 8 101 10
4.6 2.1 3.5 1.9 4.4 2.3 3.3
4.4 27.5 4.1 26.4 4.4 27.5 4.0
53 47 54
12 126 12 121 13 128 12
7 78 7 76 7 78 7
27 211 28 198 28 211 27
13 48 13 51 13 49 13
29 27 30
52 50 50
9 11 10 10 9 11 10
37 35 40
11 101 16 96 12 102 18
2.9 2.9 2.9 2.4 2.7 3.4 3.5
) 46 (13, 140) 0 (—) 57 (15, 297)
ultiply by 0.02586. *For longitudinal data, continuous variables are reported as mean  SD of
as proportion of participants with presence of risk factor at any exam during follow-up (exams 1
minations 2, 6, and 7). †C-reactive protein values are the mean of measurement at a maximum
torse Calciumsis Risk Factors
d Mitral Valve Calcium
lcium Mitral Valve Calcium
p Value Adjusted OR 95% CI p Value
2 0.0001 3.11 2.58–3.75 0.0001
6 0.0003 — — —
1 0.0001 1.26 1.08–1.48 0.004
1 0.002 0.85 0.71–1.02 0.07
0 0.008 — — —
1 0.002 1.18 1.02–1.36 0.03
— 1.29 1.10–1.52 0.002
e calcium and the following candidate independent variables as long-term average (examinations
dex, number of cigarettes smoked per day, C-reactive protein, fasting glucose, and lipid-loweringal Riciud Lo
itral
Abse
(n  8
30
59
23.9
10
117
76
180
53
0
33
18
0
99
1.9
26.0
45
120
76
193
53
27
48
9
36
95
2.4
0 (—
r liter, m
portedk Facl Valvclero
ic an
lve Ca
5% CI
76–3.8
41–0.7
50–2.0
66–0.9
05–1.4
08–1.4
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June 1, 2010:2491–8 Risk Factors for Valve Calciumramingham coronary heart disease risk score and valve
alcium. To evaluate the combined effect of multiple ath-
rosclerotic risk factors in early adulthood on valvular
alcification later in adulthood, we examined the prevalence
f valve calcification across categories of coronary heart
isease risk based on the Framingham risk score at the
aseline examination (1971 to 1975). The prevalence of
ortic valve calcium was 33.0%, 53.8%, and 61.1%, for low,
ntermediate, and high Framingham coronary heart disease
isk score categories, respectively (p  0.0001 for trend
cross risk categories) (Fig. 2). A similar relationship was
lso seen when we evaluated the severity of aortic valve
alcium (determined by mean aortic valve calcium score)
cross increasing risk score categories (p  0.006 for trend)
Fig. 3). We did not observe any significant trend for the
resence or severity of mitral valve calcium across risk score
ategories.
In a sensitivity analysis among participants 40 years of age
r younger, we noted a similar graded increase in the
ssociation of Early Atherosclerosis Risk Factors (Examinations 1ith the Presence of Aortic and Mitral Valve CalciumTable 3 Association of E rly Atherosclerosis Risk Factors (ExaWith the Presence of Aortic and Mitral Valve Calcium
Aortic Va
Adjusted OR 9
Age, per SD 2.81 2.
Female sex 0.64 0.
Mean total cholesterol, per SD 1.81 1.
Mean high-density lipoprotein cholesterol, per SD 0.84 0.
Body mass index, per SD 1.15 0.
Cigarettes smoked daily, per SD 1.22 1.
C-reactive protein, per SD (from examination 2) —
tepwise logistic regression models were constructed with outcome variables of the presence
xaminations 1 through 3: age, sex, total cholesterol, high-density lipoprotein cholesterol, bo
ntihypertensive therapy. Predictor variables with p  0.10 are presented.
Abbreviations as in Table 2.
Figure 2 Prevalence of Aortic Valve Calcium Stratified by
Framingham Risk Score Categories in Early Adulthood
Low, intermediate, and high cardiovascular risk corresponds to a 6%, 6% to
20%, and 20% 10-year risk of coronary heart disease (CHD), respectively.
Error bars represent 95% confidence intervals.revalence and severity of aortic valve calcium across risk
core categories (Fig. 4).
iscussion
rincipal findings. In our study of 1,300 participants
ith 25 years of follow-up, we identified several tradi-
ional atherosclerosis risk factors that are associated with the
resence of aortic and mitral valve calcium as detected by
ardiac MDCT. Of the modifiable risk factors, we found
hat cigarette smoking and total cholesterol were strongly
ssociated with valve calcium. We also noted important
ssociations for HDL-C and BMI with valvular calcifica-
ion. The observed associations were consistent whether we
xamined the risk factors averaged over the entire 27 years
f observation or over the first 12 years of observation. Our
tudy with 25 years of follow-up represents the longest
ommunity-based cohort to examine associations between
therosclerosis risk factors and valve calcium and provides
ew evidence that long-term exposure to an adverse risk
gh 3)tions 1 Through 3)
lcium Mitral Valve Calcium
p Value Adjusted OR 95% CI p Value
1 0.0001 2.89 2.39–3.50 0.0001
7 0.005 — — —
1 0.0001 1.33 1.13–1.57 0.0005
9 0.03 — — —
3 0.06 1.26 1.08–1.47 0.003
9 0.005 1.21 1.05–1.39 0.009
— — — —
r aortic or mitral valve calcium and the following candidate predictor variables averaged over
ss index, number of cigarettes smoked per day, fasting glucose, lipid-lowering therapy, and
Figure 3 Mean Aortic Valve Calcium Score Stratified by
Framingham Risk Score Categories in Early Adulthood
Low, intermediate, and high cardiovascular risk corresponds to a 6%, 6% to
20%, and 20% 10-year risk of coronary heart disease (CHD), respectively.
Error bars represent SEs for calcium score.Throumina
lve Ca
5% CI
39–3.3
47–0.8
55–2.1
72–0.9
99–1.3
06–1.3
—
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Risk Factors for Valve Calcium June 1, 2010:2491–8actor profile starting in early adulthood is associated with
n increased prevalence of valvular calcification measured
early 3 decades later.
n the context of the current literature. AORTIC VALVE
ALCIUM. We found that 39% of participants had aortic
alve calcium on CT. Our estimate of aortic valve calcium is
igher than that of previous reports of aortic sclerosis by
chocardiography, which have ranged from 26% to 29%
7,14) and aortic valve calcium by CT, which was reported
o be 14% (20). This may be due to differences in baseline
articipant characteristics, a predominantly white sample,
ower use of lipid-lowering therapies, differences in the
maging protocol, or differences in the CT reading meth-
dology between our study and others.
Several previous studies reported associations with cho-
esterol and aortic valve disease (7,21–25). Our longitudinal
Figure 4 Prevalence and Severity of Aortic Valve
Calcification in Participants <40 Years of Age
Prevalence of aortic valve calcium (A) and mean aortic valve calcium score (B)
stratified by the Framingham risk score in early adulthood among participants
40 years of age or younger. Low, intermediate, and high cardiovascular risk
corresponds to 6%, 6% to 20%, and 20% 10-year risk of coronary heart
disease (CHD), respectively. Error bars represent 95% confidence intervals for
prevalence and SEs for calcium score.ata with serial serum cholesterol measurements over a c7-year period support the association between lipids and
ortic valve calcium, demonstrating that for each 29-mg/dl
ncrease in the long-term average of total cholesterol, there
as a marked 74% increase in the odds of aortic valve
alcium. Associations with valve calcium have also been
eported for other cardiovascular risk factors including
igarette smoking (13,18,19,23,24), BMI (23,24), metabolic
yndrome (12,17), and hypertension (7,18,19,22,23). Our
esults confirm that cigarette smoking is a potent risk factor
or aortic valve calcification. In addition, we found a weak
ssociation between increased BMI and aortic valve calcium.
ontrary to several previous reports (7,21,22,25,26), we did
ot find any association with hypertension or blood pres-
ure; this may have been due to the younger age of our
ample or other differences in baseline characteristics. In
ddition, despite histological evidence of inflammation in
ortic calcification (27), we found no association with
lasma CRP and aortic valve calcium, which is in agreement
ith a previous study evaluating CRP and the progression
f aortic stenosis (28).
We are unaware of any previous studies that evaluated the
resence of aortic valve calcification based on coronary heart
isease risk factor profiles in early adulthood. However, our
ndings that an early adverse risk factor profile in the fourth
ecade of life is associated with increased prevalence of aortic
alve disease later in life are supported by a recent study by
wens et al. (29), who reported that the association between
ow-density lipoprotein levels and prevalent valvular calcifica-
ion was significant only among subjects younger than 65 years
f age. These observations suggest that risk factors early in life,
s opposed to later in life, may be more important for future
alvular calcification. Whether risk factor modification at an
arlier stage in life could arrest valvular damage and prevent
alvular disease in old age requires further study.
ITRAL VALVE CALCIUM. Mitral calcification also shares
any risk factors with atherosclerosis and aortic calcifica-
ion. Our findings of relationships between mitral calcifica-
ion with cigarette smoking and lipid levels are in agreement
ith those of previous studies evaluating mitral annular
alcification by echocardiography (22,23,30–32). We also
bserved an important relationship between serum CRP
nd mitral valve calcification, independent of other risk
actors, which represents, to our knowledge, a novel asso-
iation not previously reported in the literature. In our
nalysis, it remains unclear why CRP was associated only
ith mitral valve calcium and not aortic valve calcium.
hether this observation represents differences in the
athogenesis of mitral and aortic calcification or is a
ortuitous finding requires further study.
otential mechanisms. Valvular sclerosis and calcification
eem to have marked similarities with coronary atheroscle-
osis. Histologically, early valve lesions are characterized by
disruption of valvular endothelium at areas of mechanical
tress (33,34), accumulation of oxidized lipids and foam
ells, and a prominent inflammatory infiltrate (3–6,35).
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June 1, 2010:2491–8 Risk Factors for Valve Calciumhanges in the valvular microenvironment promote differ-
ntiation of valvular cells to adopt an osteoblast-like phe-
otype leading to calcification, which characterizes the
athological process (36,37). Numerous lines of experimen-
al evidence have demonstrated the importance of plasma
holesterol in this process (2,3). Once low-density lipopro-
ein is oxidized due to cigarette smoking or other factors, it
as been shown to be a major stimulus for the deposition of
xtracellular matrix required for calcium deposition (36,38).
Animal models of hyperlipidemia have also provided
dditional evidence of the integral role of lipids in valvular
alcification (39–41). In a recent study using hyperlipidemic
ransgenic mice with a “genetic switch” that allowed reversal
f the hyperlipidemic phenotype, Miller et al. (42) demon-
trated reductions in oxidative stress, lipid deposition, and
alcium deposition with arrest of further valvular sclerosis
fter hyperlipidemia was reversed. These results provide
ew evidence of the role of lipids in the initiation and early
tages of valvular disease.
linical implications. Randomized, controlled trials of
ipid-lowering therapy to reduce the development or pro-
ression of aortic valve disease have been generally disap-
ointing (8–10). These trials were limited to elderly patients
mean age across trials was 67 years) with established
oderate or severe aortic valve stenosis (mean valve area
cross these trials was 1.3 cm2 with a peak transvalvular
radient of 40 mm Hg). Our findings of strong and
onsistent associations between valve calcium and cardio-
ascular risk factors determined decades earlier raises the
ypothesis that aggressive risk factor modification at an
arlier age, among predisposed individuals, may be required
o reduce the incidence of future valvular disease (29,42).
owever, the ASTRONOMER (Aortic Stenosis Progres-
ion Observation: Measuring Effects of Rosuvastatin) trial
11), which randomized patients with less severe aortic valve
isease, also failed to demonstrate the efficacy of statins in
lowing aortic valve disease. Although participants in this
rial were younger than in previous trials, their mean age was
till 58 years; therefore, it remains possible that earlier
ipid-lowering drug therapy and risk-factor modification
sing alternative strategies (e.g., exercise) (43) before the
nitiation of valvular remodeling may be necessary to reduce
he progression to aortic stenosis.
tudy limitations. First, we used valve calcification, a
ubclinical surrogate marker for aortic or mitral valve scle-
osis, as our outcome. We therefore could not assess the
mpact on physiological correlates (i.e., valve gradients) or
n “hard outcomes” such as critical valve stenosis or valve
eplacement. However, valvular calcification is known to be
n important risk factor for the development of clinical
alvular disease and represents the same pathophysiological
rocess involved in clinical disease (1). Second, participants
id not have a CT scan on enrollment, and therefore any
aseline calcification could not be quantified. However,
iven the young age at enrollment, it is unlikely that
articipants had any calcification at this early age. Third,ue to the observational nature of our study, reported
ssociations with atherosclerosis risk factors cannot imply
ausal relationships. Last, our sample was derived from a
redominantly white population of European descent,
nd, as such, our results may not apply to other races or
thnicities.
onclusions
e found that long-term exposure to atherosclerosis risk
actors, such as plasma lipids and cigarette smoking, starting
n early to mid-adulthood are associated with both aortic
nd mitral valvular calcification. Further study is warranted
o evaluate whether early modification of cardiovascular risk
actors may also decrease the development of valvular
isease in the elderly.
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oston, Massachusetts 02114. E-mail: skathiresan@partners.org.
EFERENCES
1. Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of
aortic stenosis in patients with “benign” aortic valve thickening. Arch
Intern Med 2002;162:2345–7.
2. Chan KL. Is aortic stenosis a preventable disease? J Am Coll Cardiol
2003;42:593–9.
3. O’Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers
CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the
morphologically early lesion of ‘degenerative’ valvular aortic stenosis.
Arterioscler Thromb Vasc Biol 1996;16:523–32.
4. Olsson M, Dalsgaard CJ, Haegerstrand A, Rosenqvist M, Ryden L,
Nilsson J. Accumulation of T lymphocytes and expression of
interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am
Coll Cardiol 1994;23:1162–70.
5. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density
lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler
Thromb Vasc Biol 1999;19:1218–22.
6. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD.
Characterization of the early lesion of ‘degenerative’ valvular aortic
stenosis. Histological and immunohistochemical studies. Circulation
1994;90:844–53.
7. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated
with calcific aortic valve disease. Cardiovascular Health Study. J Am
Coll Cardiol 1997;29:630–4.
8. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of
intensive lipid-lowering therapy in calcific aortic stenosis. N Engl
J Med 2005;352:2389–97.
9. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting
aortic valve endothelium to slow the progression of aortic stenosis.
J Am Coll Cardiol 2007;49:554–61.
0. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering
with simvastatin and ezetimibe in aortic stenosis. N Engl J Med
2008;359:1343–56.
1. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER
Investigators. Effect of Lipid lowering with rosuvastatin on progres-
sion of aortic stenosis: results of the aortic stenosis progression
observation: measuring effects of rosuvastatin (ASTRONOMER)
trial. Circulation 2010;121:306–14.
2. Agmon Y, Khandheria BK, Meissner I, et al. Aortic valve sclerosis and
aortic atherosclerosis: different manifestations of the same disease?
Insights from a population-based study. J Am Coll Cardiol 2001;38:
827–34.
3. Katz R, Budoff MJ, Takasu J, et al. Relationship of metabolic
syndrome with incident aortic valve calcium and aortic valve calcium
progression: the Multi-Ethnic Study of Atherosclerosis (MESA).
Diabetes 2009;58:813–9.
11
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
K
2498 Thanassoulis et al. JACC Vol. 55, No. 22, 2010
Risk Factors for Valve Calcium June 1, 2010:2491–84. Stritzke J, Linsel-Nitschke P, Markus MR, et al. Association between
degenerative aortic valve disease and long-term exposure to cardiovas-
cular risk factors: results of the longitudinal population-based KORA/
MONICA survey. Eur Heart J 2009;30:2044–53.
5. Dawber TR, Meadors GF, Moore FEJ. Epidemiological approaches
to heart disease: the Framingham Study. Am J Public Health 1951;
41:279–86.
6. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP.
An investigation of coronary heart disease in families. The Framing-
ham offspring study. Am J Epidemiol 1979;110:281–90.
7. Rosito GA, Massaro JM, Hoffmann U, et al. Pericardial fat, visceral
abdominal fat, cardiovascular disease risk factors, and vascular calcifi-
cation in a community-based sample: the Framingham Heart Study.
Circulation 2008;117:605–13.
8. Hoffmann U, Siebert U, Bull-Stewart A, et al. Evidence for lower
variability of coronary artery calcium mineral mass measurements by
multi-detector computed tomography in a community-based cohort–
consequences for progression studies. Eur J Radiol 2006;57:396–402.
9. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H,
Kannel WB. Prediction of coronary heart disease using risk factor
categories. Circulation 1998;97:1837–47.
0. Katz R, Wong ND, Kronmal R, et al. Features of the metabolic
syndrome and diabetes mellitus as predictors of aortic valve calcifica-
tion in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006;
113:2113–9.
1. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of
coronary risk factors and use of statins with progression of mild
valvular aortic stenosis in older persons. Am J Cardiol 2001;88:693–5.
2. Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum
lipids, calcium, and phosphorus, diabetes mellitus and history of
systemic hypertension with presence or absence of calcified or thick-
ened aortic cusps or root in elderly patients. Am J Cardiol 1987;59:
998–9.
3. Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification:
characteristics of patients with calcification of the mitral annulus or
aortic valve. Heart 1997;78:472–4.
4. Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L.
Case-control analysis of risk factors for presence of aortic stenosis in
adults (age 50 years or older). Am J Cardiol 1985;55:744–7.
5. Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkila J, Tilvis
R. Factors associated with calcific aortic valve degeneration in the
elderly. Eur Heart J 1994;15:865–70.
6. Peltier M, Trojette F, Sarano ME, Grigioni F, Slama MA, Tribouilloy
CM. Relation between cardiovascular risk factors and nonrheumatic
severe calcific aortic stenosis among patients with a three-cuspid aortic
valve. Am J Cardiol 2003;91:97–9.
7. Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG,
Kaplan FS. Bone formation and inflammation in cardiac valves.
Circulation 2001;103:1522–8.
8. Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not
C-reactive protein, predict progression of calcific aortic-valve disease:
the Cardiovascular Health Study. J Am Coll Cardiol 2007;50:1992–8. y9. Owens DS, Katz R, Johnson E, et al. Interaction of age with
lipoproteins as predictors of aortic valve calcification in the multi-
ethnic study of atherosclerosis. Arch Intern Med 2008;168:1200–7.
0. Nair CK, Sudhakaran C, Aronow WS, Thomson W, Woodruff MP,
Sketch MH. Clinical characteristics of patients younger than 60 years
with mitral anular calcium: comparison with age- and sex-matched
control subjects. Am J Cardiol 1984;54:1286–7.
1. Savage DD, Garrison RJ, Castelli WP, et al. Prevalence of submitral
(anular) calcium and its correlates in a general population-based
sample (the Framingham Study). Am J Cardiol 1983;51:1375–8.
2. Fox CS, Guo CY, Larson MG, et al. Relations of inflammation and
novel risk factors to valvular calcification. Am J Cardiol 2006;97:
1502–5.
3. Thubrikar MJ, Aouad J, Nolan SP. Patterns of calcific deposits in
operatively excised stenotic or purely regurgitant aortic valves and their
relation to mechanical stress. Am J Cardiol 1986;58:304–8.
4. Zand T, Majno G, Nunnari JJ, et al. Lipid deposition and intimal
stress and strain. A study in rats with aortic stenosis. Am J Pathol
1991;139:101–13.
5. Warren BA, Yong JL. Calcification of the aortic valve: its progression
and grading. Pathology 1997;29:360–8.
6. Mohler ER 3rd, Chawla MK, Chang AW, et al. Identification and
characterization of calcifying valve cells from human and canine aortic
valves. J Heart Valve Dis 1999;8:254–60.
7. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products
have opposite effects on calcifying vascular cell and bone cell differen-
tiation. A possible explanation for the paradox of arterial calcification
in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997;17:
680–7.
8. O’Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is
expressed in human aortic valvular lesions. Circulation 1995;92:
2163–8.
9. Fazio S, Sanan DA, Lee YL, Ji ZS, Mahley RW, Rall SC, Jr.
Susceptibility to diet-induced atherosclerosis in transgenic mice ex-
pressing a dysfunctional human apolipoprotein E(Arg 112,Cys142).
Arterioscler Thromb 1994;14:1873–9.
0. Sarphie TG. Surface responses of aortic valve endothelia from diet-
induced, hypercholesterolemic rabbits. Atherosclerosis 1985;54:
283–99.
1. Zahor Z, Czabanova V. Experimental atherosclerosis of the heart
valves in rats following a long-term atherogenic regimen. Atheroscle-
rosis 1977;27:49–57.
2. Miller JD, Weiss RM, Serrano KM, et al. Lowering plasma choles-
terol levels halts progression of aortic valve disease in mice. Circulation
2009;119:2693–701.
3. Matsumoto Y, Adams V, Jacob S, Mangner N, Schuler G, Linke A.
Regular exercise training prevents aortic valve disease in low-density
lipoprotein-receptor-deficient mice. Circulation 2010;121:759–67.
ey Words: aortic valve y atherosclerosis y calcification y mitral valve
stenosis.
